Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania

• Status: Completed
• Trial end date: 2004-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the extent of symptom remission in patients with trichotillomania following treatment with sertraline and/or behavior therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: Pfizer
• Treatments: Sertraline

Criteria

Inclusion Criteria:

• Patients will have a DSM-IV diagnosis of TTM.

• TTM symptoms for at least 4 months.

• Scalp as primary site of hair pulling.

• HPS score greater than or equal to 15 OR TTM Impact Scale score greater than 30.

• Written informed consent.

• Men or women aged 18-65 years old.

• Females of childbearing potential must have a negative serum beta-HCG pregnancy test.

Exclusion Criteria:

• Pregnant women or women of childbearing potential who are not using a medically accepted means of contraception.

• Patients who, in the investigator's judgement, pose a serious suicidal or homicidal risk.

• Serious or unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease. Patients on anticoagulant therapy.

• History of seizure disorder.

• Comorbid bipolar disorder, psychosis, organic mental disorder, or developmental disorder.

• If there is a history of substance abuse, patients must be in remission at least 6 months.

• Past trials of sertraline.

• Currently being treated with behavioral therapy, specifically habit reversal training, for TTM.

• Other medications for medical disorders that may interact with sertraline.